These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11981550)

  • 1. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nat Biotechnol; 2002 May; 20(5):437-40. PubMed ID: 11981550
    [No Abstract]   [Full Text] [Related]  

  • 2. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 3. Putting a price on biotechnology.
    Stewart JJ; Allison PN; Johnson RS
    Nat Biotechnol; 2001 Sep; 19(9):813-7. PubMed ID: 11533634
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology venture capital booms in Japan.
    Saegusa A
    Nat Biotechnol; 2000 Mar; 18(3):256. PubMed ID: 10700128
    [No Abstract]   [Full Text] [Related]  

  • 5. Boosting biotech in Finland.
    Smaglik P
    Nature; 2004 Oct; 431(7011):1020-1. PubMed ID: 15496931
    [No Abstract]   [Full Text] [Related]  

  • 6. Fickle financing climate continues.
    Mitchell P
    Nat Biotechnol; 2001 Aug; 19(8):695-6. PubMed ID: 11479542
    [No Abstract]   [Full Text] [Related]  

  • 7. The number on biotech indexes.
    Jacobs T
    Nat Biotechnol; 2005 Nov; 23(11):1356. PubMed ID: 16273059
    [No Abstract]   [Full Text] [Related]  

  • 8. State of the biotech sector - 2006.
    Lawrence S
    Nat Biotechnol; 2007 Jul; 25(7):706. PubMed ID: 17621283
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 10. Tough times set to continue for US biotech start-ups.
    Lehrman S
    Nature; 1999 Jan; 397(6716):191. PubMed ID: 9930684
    [No Abstract]   [Full Text] [Related]  

  • 11. What a stock analyst can do for you.
    Jacobs T
    Nat Biotechnol; 2005 Sep; 23(9):1063. PubMed ID: 16151392
    [No Abstract]   [Full Text] [Related]  

  • 12. Australian biotech suffers growing pains.
    O'Neill G
    Nat Biotechnol; 2005 Apr; 23(4):401-2. PubMed ID: 15815652
    [No Abstract]   [Full Text] [Related]  

  • 13. Are small biotechs still underselling themselves?
    Ransom J
    Nat Biotechnol; 2006 May; 24(5):477. PubMed ID: 16680112
    [No Abstract]   [Full Text] [Related]  

  • 14. Northern England: rising star.
    Smaglik P
    Nature; 2003 Sep; 425(6956):430-3. PubMed ID: 14508497
    [No Abstract]   [Full Text] [Related]  

  • 15. NASD rule requires disclosure.
    Bouchie A
    Nat Biotechnol; 2001 Aug; 19(8):705. PubMed ID: 11491105
    [No Abstract]   [Full Text] [Related]  

  • 16. France boosts funding for biotechnology start-ups.
    Goodman S
    Nature; 2001 Dec; 414(6864):573. PubMed ID: 11740520
    [No Abstract]   [Full Text] [Related]  

  • 17. Real options for biotechnology valuation.
    Harrison M; Lerer L
    Nat Biotechnol; 2002 Mar; 20(3):223-4. PubMed ID: 11875412
    [No Abstract]   [Full Text] [Related]  

  • 18. Singapore--biotechnology development.
    Patel SH
    Clin Invest Med; 2005 Feb; 28(1):12-4. PubMed ID: 15770877
    [No Abstract]   [Full Text] [Related]  

  • 19. Ireland embraces biotechnology.
    Canning S
    Nat Biotechnol; 2000 Mar; 18(3):273-5. PubMed ID: 10700138
    [No Abstract]   [Full Text] [Related]  

  • 20. Case study: India's billion dollar biotech.
    Chakma J; Masum H; Perampaladas K; Heys J; Singer PA
    Nat Biotechnol; 2010 Aug; 28(8):783. PubMed ID: 20697399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.